Genentech's immunotherapy improves survival by two months in first-line SCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower133 trial showing that its anti-PD-L1 mAb Tecentriq atezolizumab in combination with chemotherapy led to a two-month overall survival (OS) benefit over chemotherapy alone as first-line treatment of extensive-stage small cell lung cancer (SCLC).

Genentech reported in June that IMpower133 met its co-primary endpoints of improving OS and progression-free survival (PFS). The company told BioCentury it has submitted the data to FDA and is planning to submit the data to global health authorities (see “Tecentriq Meets Endpoints in Phase III for Extensive-Stage SCLC”)...